AU5178999A - Nucleic acid delivery - Google Patents
Nucleic acid deliveryInfo
- Publication number
- AU5178999A AU5178999A AU51789/99A AU5178999A AU5178999A AU 5178999 A AU5178999 A AU 5178999A AU 51789/99 A AU51789/99 A AU 51789/99A AU 5178999 A AU5178999 A AU 5178999A AU 5178999 A AU5178999 A AU 5178999A
- Authority
- AU
- Australia
- Prior art keywords
- nucleic acid
- acid delivery
- delivery
- nucleic
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Botany (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9816583 | 1998-07-31 | ||
GBGB9816583.0A GB9816583D0 (en) | 1998-07-31 | 1998-07-31 | Nucleic acid carrier |
PCT/GB1999/002490 WO2000007630A1 (en) | 1998-07-31 | 1999-07-30 | Nucleic acid delivery |
Publications (1)
Publication Number | Publication Date |
---|---|
AU5178999A true AU5178999A (en) | 2000-02-28 |
Family
ID=10836418
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU51789/99A Abandoned AU5178999A (en) | 1998-07-31 | 1999-07-30 | Nucleic acid delivery |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU5178999A (en) |
GB (2) | GB9816583D0 (en) |
WO (1) | WO2000007630A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2412544A1 (en) * | 2000-07-24 | 2002-01-31 | Gendel Limited | Polypeptide delivery ii-2 |
WO2002057436A2 (en) * | 2001-01-19 | 2002-07-25 | Gendel Limited | Red blood cell from a transgenic animal as vehicle for polypeptide delivery |
WO2013059343A1 (en) | 2011-10-17 | 2013-04-25 | Massachusetts Institute Of Technology | Intracellular delivery |
SG11201601927SA (en) | 2013-08-16 | 2016-04-28 | Massachusetts Inst Technology | Selective delivery of material to cells |
WO2016070136A1 (en) | 2014-10-31 | 2016-05-06 | Massachusetts Institute Of Technology | Delivery of biomolecules to immune cells |
EP3218492A4 (en) | 2014-11-14 | 2018-10-10 | Massachusetts Institute Of Technology | Disruption and field enabled delivery of compounds and compositions into cells |
EP3245294A4 (en) | 2015-01-12 | 2018-05-30 | Massachusetts Institute of Technology | Gene editing through microfluidic delivery |
CA2988996A1 (en) * | 2015-07-09 | 2017-01-12 | Massachusetts Institute Of Technology | Delivery of materials to anucleate cells |
WO2017041051A1 (en) | 2015-09-04 | 2017-03-09 | Sqz Biotechnologies Company | Intracellular delivery of biomolecules to cells comprising a cell wall |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4931276A (en) * | 1987-10-30 | 1990-06-05 | Franco Robert S | Method for introducing desired agents into red blood cells |
WO1991005041A1 (en) * | 1989-09-26 | 1991-04-18 | Townes Tim M | Erythroid-specific gene expression system |
CA2150617C (en) * | 1995-02-07 | 2001-10-30 | Universite Laval | Nanoerythrosome as bioactive agent carrier |
-
1998
- 1998-07-31 GB GBGB9816583.0A patent/GB9816583D0/en not_active Ceased
-
1999
- 1999-07-30 GB GB0017761A patent/GB2350060A/en not_active Withdrawn
- 1999-07-30 WO PCT/GB1999/002490 patent/WO2000007630A1/en active Application Filing
- 1999-07-30 AU AU51789/99A patent/AU5178999A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
GB0017761D0 (en) | 2000-09-06 |
WO2000007630A1 (en) | 2000-02-17 |
GB9816583D0 (en) | 1998-09-30 |
GB2350060A (en) | 2000-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU6629200A (en) | Alpha-helical peptide nucleic acid alpha-pna | |
AU1115200A (en) | Nucleic acid arrays | |
AU4307997A (en) | Nucleic acid particle delivery | |
AU3849999A (en) | Endo-beta-n-acetylglucosaminidase gene | |
AUPQ262599A0 (en) | Gene expression | |
AU8234898A (en) | Characterising nucleic acid | |
AU5178999A (en) | Nucleic acid delivery | |
AU7813698A (en) | Nucleic acid detection | |
AU6417799A (en) | Matrix-remodeling genes | |
EP1144631A3 (en) | Insulin-synthesis genes | |
AU8234798A (en) | Categorising nucleic acid | |
AU5377599A (en) | Nucleic acids | |
AU5370696A (en) | Egf-targeted nucleic acid delivery | |
AU6871900A (en) | Tsg-like gene | |
AU1870000A (en) | Gene therapy-2 | |
AUPP964899A0 (en) | Constructional system | |
AU4513599A (en) | Nucleotide sequence | |
AU3895499A (en) | Methods and compositions for nucleic acid delivery | |
AU5314999A (en) | Modified oligonucleotides | |
AUPP058797A0 (en) | Novel gene | |
AU3991099A (en) | Human nucleic acid methylases | |
AU2003202523A1 (en) | Nucleic acid delivery vehicles | |
AU5494700A (en) | Rna metabolism proteins | |
AU4107500A (en) | Nucleic acid combination | |
AUPP704498A0 (en) | Nucleic acid sequence |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |